OrbiMed

OrbiMed is a global healthcare-only investment platform managing approximately $20 billion across public equity, private equity, and private credit/royalty strategies. The firm invests across the entire healthcare value chain — from biopharmaceuticals, medical devices, diagnostics, and drug discovery tools to digital health and healthcare services — at every stage from seed-stage startups through large publicly-traded companies. OrbiMed's core belief is that powerful long-term growth trends — aging demographics, rising healthcare spending (17%+ of GDP in the US), and continuous scientific innovation — create compelling and durable investment opportunities globally. OrbiMed positions itself as a 'one-stop shop' for healthcare financing, providing tailored capital solutions including venture equity, growth equity, structured debt, and royalty monetization. The firm is typically a lead investor and takes an active, hands-on role — often taking board seats, co-founding companies, and deploying operational team members. With offices in New York, San Francisco, Shanghai, Hong Kong, Herzliya, and London, OrbiMed invests globally across North America, Asia, and Europe, and has helped bring over 80 new healthcare therapies to patients through its venture portfolio.